186 related articles for article (PubMed ID: 38063376)
1. Recent patents in the treatment and prevention of leishmaniasis.
Shahid SK
Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376
[TBL] [Abstract][Full Text] [Related]
2. Some Scaffolds as Anti-leishmanial Agents: A Review.
Mahender T; Pankaj W; Kumar SP; Ankur V; Kumar SS
Mini Rev Med Chem; 2022; 22(5):743-757. PubMed ID: 34517799
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
[TBL] [Abstract][Full Text] [Related]
4. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
5. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
[TBL] [Abstract][Full Text] [Related]
6. Related Pentacyclic Triterpenes Have Immunomodulatory Activity in Chronic Experimental Visceral Leishmaniasis.
de Jesus JA; Laurenti MD; Antonangelo L; Faria CS; Lago JHG; Passero LFD
J Immunol Res; 2021; 2021():6671287. PubMed ID: 33681389
[TBL] [Abstract][Full Text] [Related]
7. Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent.
Olliaro PL; Shamsuzzaman TA; Marasini B; Dhariwal AC; Be-Nazir A; Mondal D; Banjara MR; Das P; Sundar S; Rijal S; Arana B; Alvar J; Argaw D; Peeling RW; Kroeger A; Matlashewski G
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005190. PubMed ID: 28125596
[No Abstract] [Full Text] [Related]
8. Molecular targets and pathways for the treatment of visceral leishmaniasis.
Jain V; Jain K
Drug Discov Today; 2018 Jan; 23(1):161-170. PubMed ID: 28919438
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
Freitas CS; Santiago SS; Lage DP; Antinarelli LMR; Oliveira FM; Vale DL; Martins VT; Magalhaes LND; Bandeira RS; Ramos FF; Pereira IAG; de Jesus MM; Ludolf F; Tavares GSV; Costa AV; Ferreira RS; Coimbra ES; Teixeira RR; Coelho EAF
Exp Parasitol; 2023 Aug; 251():108555. PubMed ID: 37247802
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro antileishmanial activity of alkylene-linked nitrofurantoin-triazole hybrids.
Zuma NH; Aucamp J; Janse van Rensburg HD; N'Da DD
Eur J Med Chem; 2023 Jan; 246():115012. PubMed ID: 36516584
[TBL] [Abstract][Full Text] [Related]
11. Antileishmanial patents antileishmanial current drugs and relevant patents.
Monzote L
Recent Pat Antiinfect Drug Discov; 2011 Jan; 6(1):1-26. PubMed ID: 21192776
[TBL] [Abstract][Full Text] [Related]
12. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
13. Treatment of leishmaniasis: a review and assessment of recent research.
Elmahallawy EK; Agil A
Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
[TBL] [Abstract][Full Text] [Related]
14. Vaccines in leishmaniasis: advances in the last five years.
Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
[TBL] [Abstract][Full Text] [Related]
15. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
Croft SL; Coombs GH
Trends Parasitol; 2003 Nov; 19(11):502-8. PubMed ID: 14580961
[No Abstract] [Full Text] [Related]
16. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
17. How I Approach Leishmaniasis: Diagnosis and Treatment in the United States.
Ness TE; Martin-Blais R; Weatherhead JE
J Pediatric Infect Dis Soc; 2022 Dec; 11(11):525-532. PubMed ID: 36043874
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of Quercetin-Loaded Nanoemulsion against Experimental Visceral Leishmaniasis:
Das SS; Dubey AK; Verma PRP; Singh SK; Singh SK
Mol Pharm; 2022 Sep; 19(9):3367-3384. PubMed ID: 35980291
[TBL] [Abstract][Full Text] [Related]
19. Unveiling the Targets Involved in the Quest of Antileishmanial Leads Using In silico Methods.
Boniface PK; Sano CM; Elizabeth FI
Curr Drug Targets; 2020; 21(7):681-712. PubMed ID: 32003668
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.
Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F
PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
